Impact Factor
3.29
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
2.39
648 total citations
h5-index
33
h5 depth signal
Cited share
61.9%
174 of 281
Total citations
648
Citation footprint
Metric signal
2.64
External metric anchor
Self-citation
8.0%
52 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
799
China
392
Japan
147
Canada
131
Italy
109
Citing Fields of Research
Cardiology
1,086
Urology
553
Diabetes
447
Autonomic Function
261
Kidney Diseases
209
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
18,028
Articles tracked across the journal lifetime
Indexed publication set
281
174 cited publications
Last 12 months
173
14.4 publications/month
Open access share
21.4%
37 OA publications in the last year
Leading citing country
United States
799 citing publications
Leading citing field
Cardiology
1,086 citing publications
Latest tracked publication
19 October 2026
10 recent records available
Coverage & Indexing History
v1n1,Jan. 1988-
v1n1,Jan. 1988-
Active Coverage
Research Focus & Classification
Indexed Subjects
Cardiology
Issuing & Sponsoring Bodies
Contributor
American Society of Hypertension
Broad Categories
Vascular Diseases
Urology
MeSH Descriptors
Hypertension
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1093/ajh/hpag123
Open DOI
Amlodipine and Nifedipine Associations with B-Type Natriuretic Peptide in Women with Hypertension and Heart Failure with Preserved Ejection Fraction
Background: Calcium channel blockers (CCBs) are frequently prescribed to manage hypertension in patients with heart failure with preserved ejection fraction (HFpEF). However, whether individual dihydropyridine agents exert uniform class ...
02
DOI 10.1093/ajh/hpag023
Open DOI
Role of office standardized blood pressure measurement model on hypertension screening in Shanghai community
Objectives: To evaluate the effect of office standardized blood pressure measurement (SBPM) model on hypertension screening in the Shanghai community. Methods: From January 1, 2019, to April 30, 2023, people aged 35 to 79 years old who u...
03
DOI 10.1093/ajh/hpag022
Open DOI
A comparative analysis of hypertension prevalence and features in sitting versus supine positions in rural areas of Liaoning Province
Background: To explore the distribution and impact of sitting and supine blood pressure measurements on the prevalence of hypertension, as well as to investigate the differences of this impact among different ages and genders. Methods: A...
04
DOI 10.1093/ajh/hpag081
Open DOI
Telmisartan–chlorthalidone fixed-dose combination at 2 chlorthalidone dose levels versus telmisartan in uncontrolled hypertension: a Phase III trial
Background: Evidence comparing different diuretic doses within fixed-dose combinations (FDCs) remains limited. We evaluated telmisartan/chlorthalidone FDCs according to chlorthalidone dose in patients with blood pressure (BP) inadequatel...
05
06
DOI 10.1093/ajh/hpag116
Open DOI
Beyond Inflammation: The NLRP3 Inflammasome as a Cellular and Mechanical Hub of Vascular Remodeling in Hypertension
Hypertension is sustained not only by abnormal vascular tone but also by structural and mechanical remodeling of resistance and conduit arteries. Although innate immune activation is recognized in hypertension, how inflammatory sensing b...
07
DOI 10.1093/ajh/hpag093
Open DOI
Aldosterone synthase inhibitors may alter how primary care treats hypertension
Hypertension guidelines recommend adding antihypertensive therapies until the blood pressure (BP) is below a specific target. If the BP is not below target with 3 medications, including a diuretic, then it is labeled resistant hypertensi...
08
DOI 10.1093/ajh/hpag084
Open DOI
The imperative for improved antihypertensives
Hypertension remains a leading modifiable risk factor for cardiovascular morbidity and mortality worldwide, yet blood pressure (BP) control rates remain suboptimal despite the availability of multiple antihypertensive drug classes. This ...
09
DOI 10.1093/ajh/hpag087
Open DOI
Aldosterone synthase inhibitors: biological rationale, mechanism of action, and results of clinical trials
Resistant and uncontrolled hypertension remain major unmet needs, with aldosterone dysregulation or frank excess increasingly recognized as a central driver. To this end, aldosterone synthase inhibitors (ASIs) represent a novel therapeut...
10
DOI 10.1093/ajh/hpag091
Open DOI
Aldosterone, the brain, and the blood pressure ceiling: a neurological case for aldosterone synthase inhibitors in resistant hypertension
Hypertension is the leading modifiable risk factor for stroke and a major contributor to cognitive impairment and dementia, with its global burden increasing alongside population aging. Hypertension promotes cerebrovascular damage throug...
Bibliographical & Catalog Notes
Title from cover.
Also issued online.
Official journal of: American Society of Hypertension, 1988-200?
(1989)19890911 Notice published Printed on acid-free paper